miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells

References

• Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. Trends Genet 2008; 24:64-9; PMID:18192061; http://dx.doi.org/10.1016/j.tig.2007.11.006
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/nature08467
   PubMed Web of Science ®Google Scholar
• Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, Lukas J. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007; 131:887-900; PMID:18001824; http://dx.doi.org/10.1016/j.cell.2007.09.040
   PubMed Web of Science ®Google Scholar
• Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD, Panier S, Mendez M, Wildenhain J, Thomson TM, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007; 318:1637-40; PMID:18006705; http://dx.doi.org/10.1126/science.1150034
   PubMed Web of Science ®Google Scholar
• Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB, Chen J. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007; 131:901-14; PMID:18001825; http://dx.doi.org/10.1016/j.cell.2007.09.041
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Rev Cancer 2012; 12:587-98; PMID:22918414; http://dx.doi.org/10.1038/nrc3342
   PubMed Web of Science ®Google Scholar
• Li L, Halaby MJ, Hakem A, Cardoso R, El Ghamrasni S, Harding S, Chan N, Bristow R, Sanchez O, Durocher D, et al. Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. J Exp Med 2010; 207:983-97; PMID:20385750; http://dx.doi.org/10.1084/jem.20092437
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Kimura M, Saio M, Era S, Okano Y. Plk1 is negatively regulated by RNF8. Biochem Biophys Res Commun 2011; 410:57-61; PMID:21635870; http://dx.doi.org/10.1016/j.bbrc.2011.05.104
   PubMed Web of Science ®Google Scholar
• Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14:475-88; PMID:23800994; http://dx.doi.org/10.1038/nrm3611
   PubMed Web of Science ®Google Scholar
• Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41:210-20; PMID:21195000; http://dx.doi.org/10.1016/j.molcel.2010.12.005
   PubMed Web of Science ®Google Scholar
• Song L, Dai T, Xie Y, Wang C, Lin C, Wu Z, Ying Z, Wu J, Li M, Li J. Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. J Mol Cell Biol 2012; 4:108-17; PMID:22158906; http://dx.doi.org/10.1093/jmcb/mjr046
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 2012; 72:4037-46; PMID:22761336; http://dx.doi.org/10.1158/0008-5472.CAN-12-0103
   PubMed Web of Science ®Google Scholar
• Huang JW, Wang Y, Dhillon KK, Calses P, Villegas E, Mitchell PS, Tewari M, Kemp CJ, Taniguchi T. Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res : MCR 2013; 11:1564-73; PMID:24088786; http://dx.doi.org/10.1158/1541-7786.MCR-13-0292
   PubMed Web of Science ®Google Scholar
• Yang L, Li Y, Cheng M, Huang D, Zheng J, Liu B, Ling X, Li Q, Zhang X, Ji W, et al. A functional polymorphism at microRNA-629-binding site in the 3'-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis 2012; 33:338-47; PMID:22114071; http://dx.doi.org/10.1093/carcin/bgr272
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res : MCR 2011; 9:1100-11; PMID:21693595; http://dx.doi.org/10.1158/1541-7786.MCR-11-0007
   PubMed Web of Science ®Google Scholar
• Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, Lieberman J, Chowdhury D. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 2009; 16:492-8; PMID:19377482; http://dx.doi.org/10.1038/nsmb.1589
   PubMed Web of Science ®Google Scholar
• Mueller AC, Sun D, Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 2013; 32:1164-72; PMID:22525276; http://dx.doi.org/10.1038/onc.2012.131
   PubMed Web of Science ®Google Scholar
• Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ, et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PloS One 2010; 5:e11397; http://dx.doi.org/10.1371/journal.pone.0011397
   PubMed Web of Science ®Google Scholar
• Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003; 63:8634-47; PMID:14695175
   PubMed Web of Science ®Google Scholar
• Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995; 55:6172-80; PMID:8521410
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012; 9:520-8; PMID:22825375; http://dx.doi.org/10.1038/nrclinonc.2012.123
   PubMed Web of Science ®Google Scholar
• George SH, Shaw P. BRCA and Early Events in the Development of Serous Ovarian Cancer. Frontiers Oncol 2014; 4:5; PMID:24478985; http://dx.doi.org/10.3389/fonc.2014.00005
   PubMedGoogle Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10.1038/nature10166
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol : official J Am Soc Clin Oncol 2012; 30:2654-63; PMID:22711857; http://dx.doi.org/10.1200/JCO.2011.39.8545
   PubMed Web of Science ®Google Scholar
• Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8:17; PMID:18208621; http://dx.doi.org/10.1186/1471-2407-8-17
   PubMed Web of Science ®Google Scholar
• Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pitta C, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011; 30:1990-2007; PMID:21468029; http://dx.doi.org/10.1038/emboj.2011.102
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010; 3:46; PMID:21106054; http://dx.doi.org/10.1186/1756-8722-3-46
   PubMed Web of Science ®Google Scholar
• Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10:42-6; PMID:19289371; http://dx.doi.org/10.3816/CLC.2009.n.006
   PubMed Web of Science ®Google Scholar
• Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010; 23:1229-34; PMID:21244772
   PubMed Web of Science ®Google Scholar
• Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11:136-46; PMID:20022810; http://dx.doi.org/10.1016/S1470-2045(09)70343-2
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68:425-33; PMID:18199536; http://dx.doi.org/10.1158/0008-5472.CAN-07-2488
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707; PMID:17875710; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110:13-21; PMID:18589210; http://dx.doi.org/10.1016/j.ygyno.2008.04.033
   PubMed Web of Science ®Google Scholar
• Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011; 12:273-85; PMID:21345725; http://dx.doi.org/10.1016/S1470-2045(11)70012-2
   PubMed Web of Science ®Google Scholar
• Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011; 15:1593-602; PMID:20716115; http://dx.doi.org/10.1111/j.1582-4934.2010.01148.x
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep 2009; 22:233-40; PMID:19578761; http://dx.doi.org/10.3892/or_00000417
   PubMed Web of Science ®Google Scholar
• Lv L, Zhang T, Yi Q, Huang Y, Wang Z, Hou H, Zhang H, Zheng W, Hao Q, Guo Z, et al. Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell cycle 2012; 11:2864-75; PMID:22801546; http://dx.doi.org/10.4161/cc.21196
   PubMed Web of Science ®Google Scholar
• Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res : an official J Am Assoc Cancer Res 2000; 6:1833-9; PMID:10815905
   PubMed Web of Science ®Google Scholar
• Roschke AV, Stover K, Tonon G, Schaffer AA, Kirsch IR. Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. Neoplasia 2002; 4:19-31; PMID:11922387; http://dx.doi.org/10.1038/sj.neo.7900197
   PubMed Web of Science ®Google Scholar
• Hall J. The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett 2005; 227:105-14; PMID:16112413; http://dx.doi.org/10.1016/j.canlet.2004.12.001
   PubMed Web of Science ®Google Scholar
• Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 2000; 92:795-802; PMID:10814674; http://dx.doi.org/10.1093/jnci/92.10.795
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol 2013; 230:347-9; PMID:23620175; http://dx.doi.org/10.1002/path.4205
   PubMed Web of Science ®Google Scholar
• Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol 2001; 11:105-9; PMID:11231126; http://dx.doi.org/10.1016/S0960-9822(01)00019-7
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol 2005; 15:43-9; PMID:15613287; http://dx.doi.org/10.1016/j.semcancer.2004.09.007
   PubMed Web of Science ®Google Scholar
• Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih Ie M, Vogelstein B, Lengauer C. The role of chromosomal instability in tumor initiation. Proc Nat Acad Sci USA 2002; 99:16226-31; PMID:12446840; http://dx.doi.org/10.1073/pnas.202617399
   PubMed Web of Science ®Google Scholar
• Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 2012; 287:34970-8; PMID:22927443; http://dx.doi.org/10.1074/jbc.M112.374611
   PubMed Web of Science ®Google Scholar
• Deng M, Ye Q, Qin Z, Zheng Y, He W, Tang H, Zhou Y, Xiong W, Zhou M, Li X, et al. miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. Tumour Biol : the J Int Soc Oncodevelop Biol Med 2013; 34:1793-800; PMID:23479198; http://dx.doi.org/10.1007/s13277-013-0718-y
   PubMedGoogle Scholar
• Wang Z, Cai H, Lin L, Tang M, Cai H. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatric Blood & Cancer 2014; 61:206-10; PMID:24038809; http://dx.doi.org/10.1002/pbc.24763
   PubMed Web of Science ®Google Scholar
• Yamane K, Jinnin M, Etoh T, Kobayashi Y, Shimozono N, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, et al. Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med 2013; 91:69-81; PMID:22828925; http://dx.doi.org/10.1007/s00109-012-0935-7
   PubMed Web of Science ®Google Scholar
• Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, Jiang J. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin. Biochem Biophys Res Commun 2012; 428:525-31; PMID:23068095; http://dx.doi.org/10.1016/j.bbrc.2012.10.039
   PubMed Web of Science ®Google Scholar
• Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011; 32:1607-14; PMID:21828058; http://dx.doi.org/10.1093/carcin/bgr184
   PubMed Web of Science ®Google Scholar
• Huang SD, Yuan Y, Zhuang CW, Li BL, Gong DJ, Wang SG, Zeng ZY, Cheng HZ. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer 2012; 11:51; PMID:22867052; http://dx.doi.org/10.1186/1476-4598-11-51
   PubMed Web of Science ®Google Scholar
• Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J 2012; 279:2393-8; PMID:22540680; http://dx.doi.org/10.1111/j.1742-4658.2012.08618.x
   PubMed Web of Science ®Google Scholar
• Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. British J Cancer 2012; 107:1361-73; PMID:22929890; http://dx.doi.org/10.1038/bjc.2012.382
   PubMed Web of Science ®Google Scholar
• Zhang ZC, Li YY, Wang HY, Fu S, Wang XP, Zeng MS, Zeng YX, Shao JY. Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PloS One 2014; 9:e86149; http://dx.doi.org/10.1371/journal.pone.0086149
   PubMed Web of Science ®Google Scholar
• Yang TS, Yang XH, Wang XD, Wang YL, Zhou B, Song ZS. MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int 2013; 13:68; PMID:23834902; http://dx.doi.org/10.1186/1475-2867-13-68
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. British J Cancer 2013; 108:479-85; PMID:23299535; http://dx.doi.org/10.1038/bjc.2012.581
   PubMed Web of Science ®Google Scholar
• Feng L, Chen J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct Mol Biol 2012; 19:201-6; PMID:22266820; http://dx.doi.org/10.1038/nsmb.2211
   PubMed Web of Science ®Google Scholar
• Higuchi R, Krummel B, Saiki RK. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 1988; 16:7351-67; PMID:3045756; http://dx.doi.org/10.1093/nar/16.15.7351
   PubMed Web of Science ®Google Scholar
• Zhang H, Jiang X, Zhang Y, Xu B, Hua J, Ma T, Zheng W, Sun R, Shen W, Cooke HJ, et al. microRNA 376a Regulates Follicle Assembly by Targeting Pcna in Fetal and Neonatal Mouse Ovaries. Reproduction 2014.
   Web of Science ®Google Scholar
• Zhang Y, Yang Y, Zhang H, Jiang X, Xu B, Xue Y, Cao Y, Zhai Q, Zhai Y, Xu M, et al. Prediction of novel pre-microRNAs with high accuracy through boosting and SVM. Bioinformatics 2011; 27:1436-7; PMID:21436129; http://dx.doi.org/10.1093/bioinformatics/btr148
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature Protoc 2006; 1:2315-9; PMID:17406473; http://dx.doi.org/10.1038/nprot.2006.339
   PubMed Web of Science ®Google Scholar
• Wang Z, Yin H, Lv L, Feng Y, Chen S, Liang J, Huang Y, Jiang X, Jiang H, Bukhari I, et al. Unrepaired DNA damage facilitates elimination of uniparental chromosomes in interspecific hybrid cells. Cell Cycle 2014; 13.
   Web of Science ®Google Scholar